Cue Health announced a new collaboration with Pfizer in the U.S. to raise awareness among individuals with certain underlying conditions about the risks of progressing to severe COVID-19 and the importance of seeking treatment if they test positive. Through Cue Care, Cue’s same-day, at-home, test-to-treatment platform, individuals will be able to use the Cue Health App to access educational resources like those available on Pfizer’s website, including information on risk factors for progression to severe illness from COVID-19, including hospitalisation or death.
This COVID-19 collaboration with Pfizer builds on recent initiatives launched by Cue to rapidly connect at-risk individuals with providers for care and, where appropriate, treatment.
Connected health solutions like the Cue platform offer potential for faster and more convenient access to care. This collaboration provides an opportunity to improve the test-to-treatment experience for patients and communities at high risk, which includes people 50 years of age and older.
Cue’s platform offers people support for each of those critical needs and is now integrating educational resources into Cue Care as part of this collaboration with Pfizer. Together, this actionable health information will help individuals make more informed decisions leading to better health outcomes.
